37results about "Antigen-carrier link" patented technology

This invention relates to the field of biotechnology, specifically to a composition containing a multivalent pneumococcal polysaccharide-protein conjugate for the prevention of pneumococcal infection and VZV infection, its preparation method, and its application. The composition of this invention, comprising a multivalent pneumococcal polysaccharide-protein conjugate, uses an immunogenic VZV recombinant protein as the carrier protein; the pneumococcal polysaccharide is covalently linked to the VZV recombinant protein; the VZV recombinant protein is selected from gE protein, and its amino acid sequence is shown in SEQ ID NO: 3 or SEQ ID NO: 4. This invention addresses the prevalence of serotypes of pneumococcus unique to my country by creatively selecting serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. This results in a composition containing polyvalent pneumococcal polysaccharide-protein conjugates designed specifically for the prevalence of these serotypes in my country.

The present invention relates to a ferritin nanocage fused with PD-L1-binding peptide 1 and a use thereof as an anticancer immunotherapy agent. Prepared in the present invention were nanocages that are formed by fusing a human ferritin monomer with a peptide 1 (PD-L1pep1: CLQKTPKQC) binding to the immune checkpoint receptor PD-L1 overexpressed in many cancers such as breast cancer, colorectal cancer, renal cancer, glioblastoma, etc. and which display 24 Pd-L1prep1. The nanocages of the present invention effectively target colorectal cancer tissues to exhibit an anticancer effect. When loading the anticancer agent doxorubicin thereinto, the nanocages showed higher anticancer effects than the same dose of PD-L1 antibody. Accordingly, the nanocages are expected as a next-generation drug that surmounts the limitation of immune checkpoint blocking therapy using antibodies.

The present invention relates to a polyvalent pneumococcal polysaccharide protein conjugate and immunogenicity thereof, and specifically provides an immunogenic composition containing capsular polysaccharides of streptococcus pneumoniae from different serotypes, and a carrier, the serotypes at least comprising 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F. The immunogenic composition can improve the immunogenicity of polysaccharides of different serotypes, and may prevent invasive infection caused by pneumococci of various different serotypes.

The present application relates to a dendritic cell-targeted allergen nanovaccine. The present application discloses a nanovaccine which is internally wrapped with an allergen and externally coupled with a dendritic cell targeting molecule. The present application also provides a preparation method and use of the nanovaccine. The nanovaccine can be specifically taken up by dendritic cells, and induce cell tolerance, and is used for specific immunotherapy of allergic diseases.

To provide a manufacturing condition related to conjugation of capsular polysaccharide from Streptococcus pneumoniae to carrier protein.SOLUTION: A method for producing a polysaccharide-protein conjugate includes allowing polysaccharide in first solution to react with protein in second solution to from third solution, and performing polysaccharide-protein conjugation reaction in the third solution to create a polysaccharide-protein conjugate, where the third solution contains at least 1 mM of salt. It is preferable that the salt be sodium salt, potassium salt, lithium salt, magnesium salt or calcium salt. A polyvalent pneumococcal vaccine can contain the polysaccharide-protein conjugate produced by using a process of the present invention.SELECTED DRAWING: Figure 1

Provided herein are compositions and methods related to CMV gB proteins in which amino acid substitutions have been made to disrupt the postfusion state and / or stabilize the prefusion state.

To provide additional pneumococcal vaccine compositions which can provide protection against pneumococcal serotypes not present in currently available vaccines.SOLUTION: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, where each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein. In some embodiments, at least one polysaccharide protein conjugate is formed by a conjugation reaction comprising an aprotic solvent. In other embodiment, each of the polysaccharide protein conjugates are formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient.SELECTED DRAWING: Figure 1

A method of encapsulating a biomolecule in a silica shell to form a particle, the method comprising: • a) hydrolyzing a mixture of silica precursors, said mixture comprising a functionalized silica precursor comprising a Si-C bond and a non-functionalized silica alkoxide precursor, • b) directly contacting the hydrolyzed precursors with an aqueous solution comprising the biomolecule and • c) encapsulating the biomolecule in a silica shell to form a particle, such that at least a portion of the silica on the interior surface of the silica shell is functionalized and comprises a Si-C bond.

The invention relates to the technical field of medicine, in particular to an antigen double burst release self-boosting immune vaccine and application thereof.The antigen double burst release self-boosting immune vaccine is characterized in that antigens are loaded inside and outside complex coacervation microcapsules in the vaccine, nanoparticles are prepared through a nanoprecipitation method, the nanoparticles and cell membranes jointly entrap the antigens to form functional nanoparticles, and the functional nanoparticles are used as functional nanoparticles; the preparation method comprises the following steps: coating functionalized nanoparticles by using a micro-fluidic technology and a complex coagulation method to prepare microcapsules, coating the surface of the microcapsules by using dopamine hydrochloride auto-polymerization reaction to form coating microcapsules, and finally blending with the functionalized nanoparticles, thereby dividing the antigen into an inner part and an outer part. After entering a body, the nano-microparticle carrier double burst release vaccine is subjected to antigen double burst release with time lag intervals in different time periods; the prepared vaccine can release antigens firstly, then effectively collect and activate antigen presenting cells, the antigen presenting cells uptake the antigen presenting cells to cause immune response, and the generation of specific antibodies can be effectively induced by two times of antigen release through the time-delay coating, so that a traditional natural immune procedure is simulated.

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.

The present invention relates to immunogenic compositions and vaccine compositions comprising the antigens AliA or immunogenic fragments thereof and PnrA and immunogenic fragments thereof from Streptococcus pneumoniae and uses thereof in the treatment and / or prevention of infections by S. pneumoniae.

The application discloses a Gitta virus genetically engineered subunit vaccine and a preparation method and application thereof, and belongs to the technical field of vaccine preparation. The Gitta virus P6E recombinant protein is obtained by using a eukaryotic expression system, and is further loaded on the surface of a nanoparticle skeleton to form a recombinant nanoparticle. The obtained recombinant protein and the recombinant nanoparticle are respectively compounded with an adjuvant to prepare the genetically engineered subunit vaccine. After twice immunization, the vaccines of the two components can significantly induce the host to produce strong humoral immune and cellular immune responses, thereby providing effective protection against GETV infection. The technical scheme of the application provides an important technical basis and application reference for research and optimization of the Gitta virus vaccine.

Chimeric antigen receptor-transduced T cells (CAR-T cells) show significant efficacy on some hematological malignancies. However, the CAR target is limited to a few antigens, which is primarily due to the non-tumor targeted toxicity of CAR-T cells. Although several strategies are proposed to avoid non-tumor targeted toxicity, the majority of which use complex designs including dual gene expression to achieve specificity. In this study, we have shown that switchable CAR immune cells (e.g., CAR-T cells) with tumor-targeting adapters can mitigate non-tumor-targeting toxicity against tumor antigens, due to which conventional CAR immune cells cannot target tumor antigens such as CD40 and CS1. Therefore, the switchable CAR system is a valuable tool for controlling the toxicity of CAR-T cells while keeping the treatment effect so as to realize CAR anti-tumor targeting expansion.

A vaccine composition comprising an oligosaccharide β - (1 → 6) - glucosamine antigen attached via a linker to a tetanus toxoid monomer carrier for providing immunity against a microorganism having a cell wall structure comprising polymeric N-acetyl - β - (1 → 6) - glucosamine structures wherein up to about 20 percent of the N-acetyl groups are deacetylated (PNAG structures), wherein the vaccine composition does not induce denaturation of the tetanus toxoid into oligomers.SOLUTION: There is provided a vaccine composition comprising a vaccine in which an antigen consisting of a penta - β - (1 → 6) - glucosamine group represented by the following partial structural formula is attached to a tetanus toxoid monomer carrier via a linker.SELECTED DRAWING: None

The present invention relates to a polyvalent pneumococcal polysaccharide protein conjugate and immunogenicity thereof, and specifically provides an immunogenic composition containing capsular polysaccharides of Streptococcus pneumoniae from different serotypes, and a carrier, the serotypes at least comprising 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F. The immunogenic composition can improve the immunogenicity of polysaccharides of different serotypes, and may prevent invasive infection caused by pneumococci of various different serotypes.

The present invention provides methods for making polysaccharide-protein conjugates in which polysaccharides, typically from bacteria, are conjugated to a carrier protein by reductive amination under conditions which improve conjugation reaction consistency, increase consumption of protein during conjugation reaction, generate conjugates of higher molecular weight, and / or reduce the levels of free cyanide in the conjugate reaction product. The polysaccharide-protein conjugates obtained using these methods are useful for inclusion in multivalent vaccines.

Provided herein are compositions and methods relating to the CMV gB protein, in which amino acid substitutions are made to disrupt the post-fusion state and / or stabilize the pre-fusion state.

Chimeric antigen receptor-transduced T cells (CAR-T cells) show a remarkable efficacy for some hematological malignancies. However, CAR targets are restricted to a few antigens primarily due to on-target off-tumor toxicities of CAR-T cells. Although several strategies were proposed to avoid on-target off-tumor toxicities, most of them use complicated designs including dual gene expression for specificity. In this study, we show that switchable CAR immune cells (e.g., CAR-T cells) with a tumor-targeting adaptor can mitigate on-target off- tumor toxicity against the tumor antigen that cannot be targeted with conventional CAR immune cells due to this toxicity, such as CD40 and CS1. Therefore, a switchable CAR system is a valuable tool to control CAR-T cell toxicity while maintaining therapeutic efficacy, which enables CAR anti-tumor target expansion.

Chimeric antigen receptor transducers (CAR-T cells) exhibit outstanding efficacy against certain hematological malignancies. However, CAR targets are limited to a small number of antigens, primarily due to the intra-target extratumor toxicity of CAR-T cells. Several strategies have been proposed to circumvent this intra-target extratumor toxicity, but most utilize complex designs, including dual gene expression for specificity. In this study, we demonstrate that switchable CAR immune cells (e.g., CAR-T cells) with tumor targeting adapters can mitigate intra-target extratumor toxicity against tumor antigens that could not be targeted by existing CAR immune cells due to toxicity, such as CD40 and CS1. Therefore, switchable CAR systems are a valuable tool for controlling CAR-T cell toxicity while maintaining therapeutic efficacy, enabling the expansion of CAR antitumor targeting.

The present invention relates to new vaccine formulations comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Vaccine formulations of the invention typically comprise at least one glycoconjugate from an S. pneumoniae serotype in a formulation designed to facilitate resuspension. [Figure 1] TIFF2025541706000005.tif58160

The present invention provides immunoconjugates comprising an antigen and an F-actin-binding moiety. These immunoconjugates promote the presentation of antigens. The invention also provides vaccines that comprise or encode conjugates tint allow antigens to be presented to the immune system. Related medical uses and methods of eliciting an immune response are also provided.

The invention discloses a Getavirus genetic engineering subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of vaccine preparation. According to the invention, a eukaryotic expression system is adopted to obtain a Geitavirus P6E recombinant protein, and further, the Geitavirus P6E recombinant protein is loaded to the surface of a nanoparticle skeleton to form recombinant nanoparticles. And respectively compounding the recombinant protein and the recombinant nanoparticles with an adjuvant to prepare the genetic engineering subunit vaccine. Through twice immunization, the vaccines of the two components can obviously induce a host to generate strong humoral immunity and cellular immunity response, so that effective protection is provided for GETV infection. The technical scheme provided by the invention provides important technical basis and application reference for research, development and optimization of Geitavirus vaccines.

Technologies for the prevention and / or treatment of pneumococcal infections.

The disclosure provides a polynucleotide comprising a nucleic acid encoding a spike epitope-loaded single-chain trimer MHC I molecule, delivery vehicles for encapsulating the polynucleotide, and methods of treatment.

Disclosed herein is a vaccine device that involves a DNA origami nanostructure formed from a plurality of scaffold strands and a plurality of staple strands assembled into a rod shape, wherein a peptide antigen is attached to the DNA of the nanostructure by electrostatic interaction. Also disclosed herein is a method for vaccinating a subject that involves administering to the subject a therapeutically effective amount of a vaccine device disclosed herein.

This disclosure subsequently provides a description of compositions and methods used to produce complex carbohydrate polypeptides using an enzyme that forms glycosidic bonds that form isopeptide bonds using a second polypeptide containing a polypeptide tag, and also provides a description of the use thereof.

The present invention provides methods for making polysaccharide-protein conjugates in which polysaccharides, typically from bacteria, are conjugated to a carrier protein by reductive amination under conditions which improve conjugation reaction consistency, increase consumption of protein during conjugation reaction, generate conjugates of higher molecular weight, and / or reduce the levels of free cyanide in the conjugate reaction product. The polysaccharide-protein conjugates obtained using these methods are useful for inclusion in multivalent vaccines.

The present disclosure provides descriptions of compositions and methods for the production of glycoconjugate polypeptides using a glycosidic bond forming enzyme that then forms an isopeptide bond with a second polypeptide containing a polypeptide tag, as well as the use of the glycoconjugate polypeptides.

The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The application discloses a porcine Gertvirus and porcine encephalitis virus B double gene engineering subunit vaccine and a preparation method and application thereof. The core components of the vaccine are Gertvirus P6E recombinant protein and encephalitis virus B DFN fusion protein, and a recombinant nanoparticle loaded with the antigens. The obtained recombinant protein or recombinant nanoparticle is compounded with an adjuvant to prepare the GETV / JEV double gene engineering vaccine, and the GETV / JEV double gene engineering vaccine can induce strong humoral and cellular immune responses of a host after two immunizations, and effectively protects the body from GETV and JEV infection. The technical scheme of the application provides important reference and technical support for developing the GETV / JEV double vaccine with high safety, high immunogenicity and suitable for large-scale production.